Supreme Court Won't Hear Patent Dispute Over Cox-2 Inhibitors

Law360, New York (November 30, 2004, 12:00 AM EST) -- The U.S. Supreme Court has refused to hear the University of Rochester’s appeal in its patent dispute with makers of cox-2 inhibitor pain killers, ending a legal battle that has cost the school $10 million.

Without explanation, the high court denied the school's request for a review of lower court rulings that dismissed its patent infringement claims against Pfizer Inc. and Merck & Co. over the class of anti-inflammatory drugs.

"We are, of course, very disappointed in the Supreme Court's decision," University of Rochester President Thomas...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.